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Abstract: Mental disorders including depression and anxiety are the prevalent human diseases which are associated with several metabolic and 
non-metabolic diseases. Recent investigations demonstrated that the mental disorders can be considered as the potential inducers/stimulators of 
chronic inflammation. Based on the fact that chronic inflammation is a main cause of human diseases, hence, a hypothesis has been raised to 
explore the interaction between mental disorders and inflammation related metabolic diseases. Type 2 diabetes (T2D), as a complicated metabolic 
disorder, is associated with inflammation and also mental disorders. Accordingly, it has been hypothesized that depression and anxiety, as mental 
disorders may be the inducers/stimulators of inflammation in the patients suffering from T2D. This review article collected recent information 
regarding the roles of mental disorders on the chronic inflammation in the T2D patients.
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Introduction
Type 2 diabetes (T2D) is a metabolic disorder which 
is associated with several complications including phy-
sical and mental disorders (1). The accurate ranges 
of mental disorders in T2D are variable and different 
among various ethnics (2). The main mechanisms which 
lead to induction of mental disorders in the patients have 
yet to be clarified. There are several hypothesis which 
are controversy regarding the etiology of mental disor-
ders in the patients suffering from T2D. For example, 
it has been hypothesized that high blood glucose levels 
in the patients can alter behavioral functions of the pa-
tients (2). Recent data proposed that inflammation can 
be considered as a main cause of mental disorders in 
the patients (3). It appears that T2D related inflamma-
tion can modulate several behavioral functions which 
have been reported in several diseases. Based on the 
fact that the prevalence of the mental disorders is dif-
ferent among human population suffering from T2D (2), 
hence, it may be hypothesized that the pro-inflammato-
ry molecules expression may be differ in the population. 
Thus, the main aim of this review article is to explore 
the prevalence of mental disorders among T2D patients 
which are reported from researchers from all over the 
world. Another aim of this article is to evaluate the roles 
played by inflammation in the induction/stimulation of 
mental disorders in the patients with T2D. Accordingly, 
the next sections describe T2D, mental disorders which 
are explored in this review article and some inflammato-
ry molecules which are associated with mental disorders 
in T2D. Finally, the link between T2D, mental disorders 
and inflammatory molecules will be discussed.
Type 2 diabetes
T2D is a chronic metabolic disease which is asso-
ciated with increased blood glucose (fasting plasma 
glucose ≥ 126 ± 7 mg/dl), insulin resistance, and in 
some cases relative lack of insulin (4). It has been esti-
mated that more than 7 % of the world’s adult popula-
tion will affected with diabetes (5). This is a prevalent 
metabolic disorder in either developed or developing 
countries. T2D is a high prevalent disease in Iran with 
more than 24 percent involvement in adult (> 40 years) 
(6). Increased blood sugar in the patients is an important 
cause of several complications including cardiovascular 
diseases, neuropathy, retinopathy, kidney failure, ampu-
tations and so on (4, 7). Obesity, unsuitable diet, not 
enough exercise, genetics, hormones and environmen-
tal factors are the main reasons for insulin resistance but 
some environmental factors such as stress and mental 
diseases deteriorate the disease (5, 8). Inflammation is a 
common phenomenon in T2D which is associated with 
the mentioned complications (1, 9).
 
Mental disorders
Mental disorders are a set of diseases which are as-
sociated with alteration of behavioral functions in the 
patients (10). The disorders affect human life quality 
and lead to several complications in some cases (11). 
Among the mental disorders, depression and anxiety are 
the most prevalent forms (12), hence, this review article 
focuses on the mental disorders. Depression is a kind of 
mental disorders which the affected patients have not 
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enough motivation to perform his/her routine functions. 
The patients suffer from a chronic inappetence, altera-
tion in sleep and weight, qualm and also self-destruc-
tion (13). Severe depression is associated with severe 
impairment in personal and social life and may result in 
overshadow of the patients health (13). 
Anxiety, as another mental unpleasant emotional 
disorder, is associated with fear, worries, continual tire-
dness, headache, exhaustion, fear of socializing, nausea, 
an upset stomach and so on. Although, the symptoms 
are defined for anxiety but they can also be exhibited 
with other mental disorders. Obviously, chronic anxiety 
makes the patients lives difficult (12). 
Scientists believe that several mechanisms may in-
duce/stimulate depression and anxiety in T2D including 
high blood sugar, chronic inflammation and so on. Inte-
restingly, the mental disorders may be the main reason 
of induction of inflammation in the patients. Next sec-
tions discuss the prevalence of depression and anxiety 
in the patients suffering from T2D and the relation of 
the mental disorders with inflammation.
 
Inflammatory molecules
There are several molecules which induce/stimulate 
inflammation in human and known as inflammatory 
molecules. Here we describe the important inflamma-
tory molecules which are evaluated in T2D with and 
without mental disorders briefly. 
Innate and adaptive immune cells are the main source 
of pro-inflammatory molecules including cytokines, co-
stimulatory molecules, pro-inflammatory surface mole-
cules and so on (14). They produce the molecules fol-
lowing interaction of PAMPs (Pathogen associated mo-
lecular patterns) and DAMPs (Damage associated mole-
cular patterns) with their pathogen recognition receptors 
(PRRs) (14). Toll like receptors (TLRs), inflammasomes 
and intracellular sensors are the main PRRs which uses 
several intracellular signaling molecules such as mye-
loid differentiation primary response (MYD88) and 
TIR-domain-containing adapter-inducing interferon- β 
(TRIF) to activate transcription factors for transcription 
from pro-inflammatory molecules (14). The main target 
of the PRRs pathways are nuclear factor kappa-light-
chain-enhancer of activated (NF-κB), interferon regula-
tory factors (IRFs) and activator protein-1 (AP-1) (15). 
The transcription factors transcript from pro-inflamma-
tory cytokines (including interleukin (IL)-1, IL-6, IL-8, 
IL-12, IL-18, interferon-gamma (IFN-γ), tumor necro-
sis factor (TNF-α) and so on), co-stimulatory mole-
cules and pro-inflammatory surface molecules (such as 
CD40, CD40L and so on) (14). The pro-inflammatory 
factors induce inflammation in responses to PAMPs and 
DAMPs in infectious diseases and inflammatory based 
diseases, respectively (14). 
Mental disorders as main inducers of inflammation
It has been hypothesized that depression and an-
xiety may be considered as modulators of immune sys-
tem functions. Recent information also confirmed the 
hypothesis which showed alteration in immune cells 
functions in the patients suffering from depression and 
anxiety (16). The published data regarding the relation 
between depression/anxiety with expression and func-
tions of immune system related molecules showed that 
the mental diseases induce inflammation in various man-
ners. Some of the literatures indicated that the mental 
disorders up-regulate pro-inflammatory molecules, and 
others revealed that depression/anxiety have reduced 
expression of the regulatory molecules. For example, 
our previous investigations revealed that depression can 
increase expression of two important adaptor proteins in 
the intracellular pathways of TLRs (MYD88 and TRIF), 
the main innate immunity cell receptors (16). As men-
tioned in the previous section, MYD88 and TRIF play 
key roles in transition of intracellular signaling from 
TLRs to down-stream molecules (17). Previous section 
showed that TLRs active corresponded cells via interac-
tion with PAMPs and DAMPs (17). It has been repor-
ted that several DAMPs including C-reactive protein 
(CRP), heat shock proteins (HSPs), high mobility group 
box-1 (HMGB1) and serum amyloid proteins (SAPs) 
are increased in depression (18-21). A study by Priya 
et al., revealed that anxiety has a positive relation with 
inflammation (22). Bakhsh-Aliabad et al., also showed 
that anxiety is an inducer of CD36 expression on the 
monocytes  of  the patients with chronic  hepatitis  B 
(23). CD36 is a scavenger receptor and participates 
in several inflammatory functions of monocytes (24). 
Additional studies showed that serum levels of anti-in-
flammatory cytokines were decreased in the depressed 
patients (25-28). Decreased expression of anti-inflam-
matory cytokine is associated with increased inflam-
matory functions of immune system and inflammation 
induction (29). Increased expressions of pro-inflamma-
tory cytokines in the patients with depression and an-
xiety have also been reported by several investigators 
(30-33). A study by Grinberg et al., demonstrated that 
the microglia cells of depressed patients have produced 
more levels of pro-inflammatory cytokines in compa-
rison to healthy controls (34). Snyder and colleagues 
reported anti-depressant drugs reduced serum levels 
of pro-inflammatory cytokines (35). Interestingly, in-
creased expression of pathogen recognition receptors 
including TLRs and inflammasomes by mental disor-
ders have been reported in previous investigations (21, 
36). Our previous study demonstrated that mRNA levels 
of NF-κB, as a transcription factor, decreased in the de-
pressed patients (37). Based on the fact that following 
interaction between TLRs and their ligands and sub-
sequently activation of intracellular signaling pathways, 
NF-κB is separated from Iκκ, the inhibitor of NF-κB, 
and translocated to the nucleus for transcription from 
pro-inflammatory molecules (15), hence, it seems that 
activation of the pathways do not need up-regulation of 
NF-κB. 
In contrast with the results, no alteration in the in-
tracellular signaling molecules of TLRs in hepatitis B 
infected patients with mental disorders have been repor-
ted when compared with hepatitis B infected patients 
without mental disorders (38). No relation between 
anxiety and serum levels of IL-1 β, IL-6 and IL-8, as 
pro-inflammatory cytokines and IL-10, as anti-inflam-
matory cytokine, have been reported by Ataseven and 
colleagues (39).
Although, the studies showed a negative relation 
between some pro-inflammatory molecules and men-
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CRP were also reported by several investigators (63, 
64). Increases expression of pro-inflammatory mole-
cules like CD40, CD40 ligand (CD40L), soluble CD40L 
(sCD40L), selectin P (CD62P), β-thromboglobulin and 
platelet factor-4 has been reported in the patients with 
T2D and depression simultaneously (65). Anxiety also 
has a positive relation with higher serum levels of pro-
inflammatory cytokines in women with diabetes (66). 
As mentioned in the previous sections, the pro-in-
flammatory molecules including cytokines and other 
molecules like CRP, CD40, CD40L and so on, are the 
down-stream molecules for PRRs (15). Based on the 
increased expression of the pro-inflammatory mole-
cules in the mental disorders during T2D, it seems that 
PRRs and their ligands (PAMPs and DAMPs) may be 
involved in the inflammatory condition linked between 
T2D and mental disorders. Interestingly, previous stu-
dies approved the hypothesis and revealed that expres-
sion of TLRs and inflammasomes, as PRRs, are signi-
ficantly increased in T2D patients and also the patients 
suffering from depression and anxiety (16, 67-69). 
Moreover, anti-anxiety and anti-depression therapy in 
a Chinese population leads to down-regulation of TLR4 
and its intracellular signaling pathways (70). Based on 
the fact that TLR4 is a unique TLR which uses both 
adaptor proteins (MYD88 and TRIF), and based on the 
fact that both adaptor proteins are increased in depres-
sion (69) and additionally, TLR4 plays key roles in the 
pathogenesis of T2D (71), hence, it seems that there as a 
potential link between mental disorders like depression 
and anxiety with T2D via TLR4 and its intracellular 
signaling molecules. Additionally, it has been identified 
that other PRRs may participate in the pathogenesis of 
T2D and its related mental disorders (1). For example, 
high-fat diet, which is associated with T2D, induces 
anxiety via activation of extracellular signal-regula-
ted kinase (ERK) and inflammasomes pathways (72). 
Diet-induced obesity also can induces depression and 
anxiety in T2D through increased endogenous LPS and 
activation of brain IDO (3). Both of the investigations 
approved the link between depression/anxiety and T2D.
Conclusion
As mentioned in the previous sections, pro-inflam-
matory cytokines, co-stimulatory molecules and sur-
face pro-inflammatory molecules (like CD40, CD40L 
and so on) increased in the patients suffering from T2D 
and mental disorders. The pro-inflammatory molecules 
are the target of TLRs and inflammasomes signaling 
pathways. Increased expression of TLRs and their intra-
cellular signaling such as MYD88 and TRIF as well as 
inflammasomes in depression/anxiety and also T2D has 
been reported previously (16, 67-69). Previous investi-
gations also revealed that several DAMPs (ligands for 
PRRs) are released during T2D and the mental disorders. 
Therefore, it seems that depression and anxiety may de-
teriorate T2D complications by increasing the endoge-
nous DAMPs and consequently activation of PRRs and 
production of pro-inflammatory molecules which are 
the main causes of T2D complications. The hypothesis 
have been approved by Pomytkin et al., which showed 
that increases intestinal peripheral serotonin (5-HT) and 
decreased serotonin tranporter (5-HTT) functions leads 
tal disorders but more than 90 percent of investigations 
approved the hypothesis. Thus, it seems that depression 
and anxiety, as mental disorders can be associated with 
inflammation.
Epidemiology of depression and anxiety in the pa-
tients with T2D
It has been documented that depression increases 
risk of reduced diabetes-related life quality in T2D (40). 
Furthermore, investigations demonstrated that mental 
disorders like depression can deteriorate T2D related 
complications such as neuropathy (41). Interestingly, 
it seems that depression history can affect T2D onset 
(42). There are several studies which have evaluated the 
prevalence of depression and anxiety in the patients suf-
fering from T2D. Accordingly, Arshad et al., revealed 
that 51 percent of Pakistani T2D patients suffered from 
depression (43). Another study on an USA population 
(2182 cases) demonstrated that 10.6 percent of partici-
pants were depressed (44). Cols-Sagarra and colleagues 
showed that the prevalence of depression among a Spa-
nish population were 29.2% (45). A study in Malaysia 
identified that 41.7% of 700 patients with T2D suffered 
from depression (46). High prevalence depression and 
anxiety in T2D patients were also reported in Germany 
(47), Japan (48), Taiwan (49), Saudi Arabia (50), South 
Korea (51), Brazil (52), Italy (53), China (54), Bangla-
desh (55), Norway (56), Iran (57) and so on.
Due to the huge reports regarding the high prevalence 
of depression and anxiety among the patients with T2D, 
it seems that the mental disorders may be considered as 
responsible for some of complications in the population. 
Based on the relation between depression/anxiety and 
inflammation induction, a hypothesis has been raised 
which propose that depression and anxiety may partici-
pate in deterioration of increased blood glucose and also 
induction of T2D complications via induction/stimula-
tion of inflammation. Accordingly, a study reported that 
antidepressant medication leads to improvement of gly-
caemic control (58). Next section evaluates the recent 
information regarding the hypothesis. 
   
Relation between mental disorders and inflamma-
tion in T2D
According to the information presented in the pre-
vious sections, it seems that depression and anxiety 
are potentially associated with increased inflammation. 
Thus, they have been considered as potential candidate 
for induction/stimulation of inflammation in the T2D 
patients, the individuals who suffer from inflammation. 
Interestingly, recent data also confirmed the hypothesis 
and revealed that depression induces expression of CRP, 
IL-6 and TNF-α, as pro-inflammatory molecules in el-
derly patients with T2D (59). Increased serum levels of 
CRP in depressed patients with T2D have been repor-
ted by Au and colleagues (60). A positive association 
between depression and CRP levels in the patients with 
T2D has been demonstrated (61). Laake et al., showed 
that depression leads to up-regulation of CRP, IL-1β, 
IL-1 receptor antagonist (IL-1RA), monocyte chemo-
tactic protein-1 (MCP-1) and white blood cell count 
(WBC) in T2D (62). Increased serum levels of IL-6 and 
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to endotoxaemia and consequently leading to TLR4 
activation which is a common mechanism for induc-
tion of inflammation in the T2D and depression (73). 
According to the information it seems that both men-
tal disorders and T2D can be considered as risk factor 
for each other, because all of them are the inducers of 
inflammation and the inflammation not only can induce 
the onset of the diseases but also is able to deteriorate 
them. For approving the hypothesis a 6 years prospec-
tive cohort study demonstrated that depression is a risk 
factor for insulin resistance and consequently increased 
risk of T2D (74). McIntyre and colleagues also reported 
that reduced volumes in areas of the depression brain 
implicated (like hippocampus and amygdale) are asso-
ciated with T2D (75). It appears that mental disorders 
and T2D affect each other via up-regulation of pro-in-
flammatory molecules. Figure 1 illustrates the relation 
between mental disorders and induction/stimulation of 
inflammation and its plausible relation with type 2 dia-
betes. Several mechanisms may participate in the inte-
raction between mental disorders and T2D, for example 
it appears that inflammatory cytokines can interact with 
synaptic plasticity, neurotransmitter metabolism and 
neuroendocrine function which are associated with both 
mental disorders and T2D. Collectively, it seems that 
inflammation is the potential link between mental disor-
ders and T2D and it may be hypothesized that therapeu-
tic strategies need to be directed to regulate inflamma-
tion in the patients.
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